Comparison of Efficacy and Safety of Tegacycline combined with Xuebijing and Cefoperazone Sulbactam in the treatment of Carbapenem-resistant Acinetobacter Baumannii Infection
MA Xin, ZHENG Jingjing, ZHANG Jie, et al
Chengde Hospital of Traditional Chinese Medicine, Hebei Chengde 067000, China
Abstract：Objective: To investigate investigate the efficacy and safety of tigacycline combined with Xuebijing and cefoperazone sulbactam in the treatment of carbapenem-resistant Acinetobacter baumannii infection. Methods: From February 2016 to February 2017, 92 patients with carbapenem-resistant Acinetobacter baumannii pneumonia were randomly divided into study group (n = 46) and control group (n = 46). Patients in the study group were treated with tegacycline combined with Xuebijing, while patients in the control group were treated with tegacycline combined with cefoperazone sulbactam. The clinical efficacy, bacterial clearance rate, inflammatory response related indicators [C-reactive protein (CRP), white blood cell count (WBC), procalcitonin (PCT)], disease development and adverse reactions were compared between the two groups. Results: The total effective rate and bacterial eradication rate in research group were 91.30% and 78.26%, which were higher than 71.74% and 58.70% in control group (P<0.05); After treatment, the CRP, WBC, PCT levels, CPIS and APACHE II scores in research group were lower than those before treatment and control group (P<0.05); The total incidence of adverse reactions in research group was 6.52%, which was lower than 21.74% in control group (P<0.05); After treatment, the levels of BUN and Scr in control group were higher than those in research group (P<0.05). Conclusion: Tigecycline cobined with Xuebijing in treatment of carbapenem-resistant Acinetobacter baumannii is effective. It can increase the bacterial eradication rate, reduce inflammatory response and have high safety, which has better curative effects compared with tigecycline cobined with cefoperazone-sulbactam.
马新,郑晶晶,张杰,周志安,边树伟,白艳. 替加环素分别联合血必净与头孢哌酮舒巴坦治疗耐碳青霉烯泛耐药鲍曼不动杆菌感染的疗效及安全性比较[J]. 河北医学, 2018, 24(11): 1857-1861.
MA Xin, ZHENG Jingjing, ZHANG Jie, et al. Comparison of Efficacy and Safety of Tegacycline combined with Xuebijing and Cefoperazone Sulbactam in the treatment of Carbapenem-resistant Acinetobacter Baumannii Infection. HeBei Med, 2018, 24(11): 1857-1861.
[1] 臧会玲,王生池,程慧,等.替加环素联合头孢哌酮/舒巴坦治疗多重耐药及泛耐药鲍曼不动杆菌临床效果分析[J].中国综合临床,2016,32(1):41~43. [2] Karuniawati A,Saharman YR,Lestari DC.Detection of carbapenemase encoding genes in enterobacteriace, pseudomonas aeruginosa, and acinetobacter baumanii isolated from patients at intensive care unit cipto mangunkusumo hospital in 2011.[J].Acta Med Indones,2013,45(2):101~106. [3] 单靖岚,郑贵星,邓穗燕,等.替加环素联合亚胺培南对多重耐药鲍曼不动杆菌的体外抗菌活性研究[J].中国药业,2016,25(10):12~14. [4] 《抗菌药物临床试验技术指导原则》写作组.抗菌药物临床试验技术指导原则[J].中国临床药理学杂志,2014,30(9):844~856. [5] Senok A,Garaween G,Raji A,et al.Genetic relatedness of clinical and environmental Acinetobacter baumanii isolates from an intensive care unit outbreak.[J].J Infect Dev Ctries,2015,9(6):665~669. [6] 蓝敏,何许伟,邓俊义,等.替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍曼不动杆菌的临床疗效评价[J].中国微生态学杂志,2016,28(2):181~184. [7] 许国斌,朱金强,张近波,等.替加环素联合头孢哌酮／舒巴坦治疗泛耐药鲍曼不动杆菌老年重症肺炎的临床疗效[J].中国老年学杂志,2016,36(7):1649~1650,1651. [8] 何先弟,颜培娥,邹琪,等.血必净对鲍曼不动杆菌脓毒症大鼠中性粒细胞翻译控制肿瘤蛋白表达的影响[J].中国临床药理学与治疗学,2014,19(1):29~32. [9] Kumar A,Randhawa VS,Nirupam N,et al.Risk factors for carbapenem-resistant Acinetobacter baumanii blood stream infections in a neonatal intensive care unit, Delhi, India.[J].Infect Dev Ctries,2014,8(8):1049~1054. [10] Zhao CJ,Chen HB,Wang H,et al.Analysis of pathogen spectrum and resistance of clinical common organisms causing bloodstream infections, hospital-acquired pneumonia and intra-abdominal infections from thirteen teaching hospitals in 2013[J].Zhonghua Yi Xue Za Zhi,2015,95(22):1739~1746. [11] 金剑虹,洪郁芝,徐新鹏,等.血清 CRP 与 PCT 在糖尿病足感染病情严重程度及预后评估价值研究[J].中华医院感染学杂志,2016,26(24):5616~5618.
2018, Vol. 24 
冀公网安备13080202000677号